New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
15:29 EDTMNKDFDA approves Afrezza to treat diabetes
The U.S. Food and Drug Administration today approved Afrezza Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal. Afrezza has a Boxed Warning advising that acute bronchospasm has been observed in patients with asthma and chronic obstructive pulmonary disease. Afrezza should not be used in patients with chronic lung disease, such as asthma or COPD because of this risk. The most common adverse reactions associated with Afrezza in clinical trials were hypoglycemia, cough, and throat pain or irritation. The FDA approved Afrezza with a Risk Evaluation and Mitigation Strategy, which consists of a communication plan to inform health care professionals about the serious risk of acute bronchospasm associated with Afrezza. The FDA is requiring the following post-marketing studies for Afrezza: a clinical trial to evaluate pharmacokinetics, safety and efficacy in pediatric patients; a clinical trial to evaluate the potential risk of pulmonary malignancy with Afrezza, which will also assess cardiovascular risk and the long-term effect of Afrezza on pulmonary function; two pharmacokinetic-pharmacodynamic euglycemic glucose-clamp clinical trials, one to characterize dose-response and one to characterize within-subject variability. Afrezza is manufactured by MannKind.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
05:48 EDTMNKDStocks with implied volatility movement; MNKD TWTR
Subscribe for More Information
May 27, 2015
16:03 EDTMNKDOptions Update; May 27, 2015
iPath S&P 500 VIX Short-Term Futures down 82c to 18.56 Option volume leaders: AAPL KORS BRCM MCD FB MNKD AAL YHOO BAC MU ANF S EOX
May 19, 2015
16:01 EDTMNKDOptions Update; May 19, 2015
iPath S&P 500 VIX Short-Term Futures down 27c to 19.17. Option volume leaders: AAPL BAC WMT MSFT FB TWTR MNKD NFLX T PBR
May 18, 2015
05:50 EDTMNKDStocks with implied volatility movement; BBRY MNKD
Stocks with implied volatility movement; BlackBerry (BBRY) 55, MannKind (MNKD) 75 according to iVolatility.
May 15, 2015
08:23 EDTMNKDJefferies sees 'good interest' in MannKind's Afrezza
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use